University of Texas Southwestern

5323 Henry Hines Blvd
Dallas, TX 75390
United States
Call 214-648-4717 Email this location
University of Texas Southwestern (UTSW) is one of twenty-five type 1 diabetes TrialNet International Clinical Centers at the forefront of type 1 diabetes research. Led by Philip Raskin, MD, the TrialNet team at UTSW is dedicated to preventing type 1 diabetes and stopping disease progression by preserving insulin production before and after diagnosis.

Our Team

Principal Investigators 
Philip Raskin, M.D., is a Professor of Internal Medicine in the Division of Endocrinology at UT Southwestern in Dallas. Both his patient care and clinical research focus on diabetes. Dr. Raskin is the holder of the Clifton and Betsy Robinson Chair in Biomedical Research. After receiving his medical degree from the University of Pittsburgh School of Medicine, Dr. Raskin stayed there to complete his residency in internal medicine. He then performed a fellowship in endocrinology, diabetes, and metabolism at UT Southwestern. Currently, Dr. Raskin is the Director of the Diabetes Clinic at Parkland Hospital. He is the Principal Investigator in four NIH-funded multicenter diabetes trials: The Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC), TrialNet, The Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE Study), and Vitamin D to Prevent Type 2 Diabetes (D2d Study).
Research Coordinators 

Regional Affiliates

Affiliates provide opportunities for people who do not live near a TrialNet Clinical Center. The affiliate sites listed below work with UTSW to offer convenient participation in our research programs

University of New Mexico School of Medicine
UNM SOM INT MED MSC10_5550, 1 Univ of NM, Albuquerque, NM 87131


Texas Tech University - Amarillo
1400 S. Coulter, Suite 4301, Amarillo, TX 79106


Texas Diabetes and Endocrinology, P.A.
6500 N. Mopac Expwy, Bldg 3 Ste 200, Austin, TX 78731


Childrens Hospital of Austin
1301 Barbara Jordan Blvd, Suite 200, Austin, TX 78723


Texas Tech University H.S.C. Lubbock
3601 4th St, STOP 9406, Lubbock, TX 79430

Oklahoma City

The University of Oklahoma
1200 Children's Ave Ste 4D, Oklahoma City, OK 73104

Oklahoma City

Pediatric Endocrinology and Clinical Genetics
3366 NW Exp St 330, Oklahoma City, OK 73112

San Antonio

Univ. of Texas Health Science Ctr.
4201 Medical Dr, Ste 104, San Antonio, TX 78239


The University of Oklahoma-Tulsa Campus
4444 East 41st Street, Tulsa, OK 74135

Research Studies

Risk Screening

Pathway to Prevention

If you have a relative with T1D, you’re in a unique position to help us learn more about the disease and how to stop it. The first step is to sign up for Pathway to Prevention screening to determine your risk of developing T1D.


Prevention Study


TrialNet is testing the drug abatacept to see if it can delay or prevent progression of early stage T1D (stage 1 to stage 2) and ultimately prevent clinical diagnosis (stage 3). In earlier studies for people newly diagnosed (stage 3), abatacept helped slow down disease progression.



We are testing the drug teplizumab to see if it can delay or prevent progression of early stage T1D (stage 2) and prevent clinical diagnosis (stage 3). In earlier studies in people newly diagnosed (stage 3), teplizumab helped to prolong insulin production.



Long-Term Investigative Follow-Up in TrialNet (LIFT)

Once your study ends, we're still here for you. Participant monitoring and continued involvement helps us learn more about T1D.